Non-small cell lung cancer (NSCLC) causes approximately 80–85% of lung cancer deaths1,2 and mutations associated with the anaplastic lymphoma kinase (ALK) gene occur in 3–8% of lung cancer patients3,4. This evidence concerns the gene ALK and lung carcinoma.